查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014387

重症醫學市場：2026-2032年全球市場預測（按產品類型、給藥途徑、患者族群、治療應用和最終用戶分類）

Critical Care Therapeutics Market by Product Type, Administration Routes, Patient Demographics, Therapeutic Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年重症監護藥物市場價值 14.8 億美元，預計到 2026 年將成長至 15.7 億美元，複合年成長率為 5.66%，到 ​​2032 年將達到 21.8 億美元。

主要市場統計數據
基準年 2025 14.8億美元
預計年份：2026年 15.7億美元
預測年份 2032 21.8億美元
複合年成長率 (%) 5.66%

全面概述了影響重症監護醫學未來的臨床重點、營運壓力和戰略意義。

目前重症監護正處於戰略十字路口，臨床需求、技術進步和政策趨勢在此交匯。醫療系統和採購領導者面臨著建立更具韌性的供應鏈、採用循證療法和醫療設備以及使資金配置與新興臨床重點保持一致的壓力。本導言旨在為後續分析提供框架，引導讀者了解影響急性照護環境中臨床實踐、醫療設備使用和治療方法選擇的各種因素。

監測、治療方法和基於價值的獎勵方面的創新如何重塑重症監護的臨床路徑和價值鏈優先事項。

過去幾年，監測、藥理學和系統韌性方面的進步共同重塑了重症監護的模式。遠端監測設備和封閉回路型輸液系統已從原型階段過渡到臨床應用，改變了床邊護理的節奏，並能夠更早發現生理衰退。同時，人們越來越關注透過藥物最佳化（特別是鎮靜策略和神經肌肉阻斷劑）來縮短人工呼吸器時間和減少相關併發症的方案。

本研究評估了 2025 年美國關稅措施對營運和採購的影響，以及這些措施如何改變了採購、價格彈性和臨床連續性。

美國2025年實施的關稅措施的累積影響，在採購、製造和臨床運營的各個領域都造成了顯著的摩擦，促使整個價值鏈即時採取戰略應對措施。關稅導致投入成本增加，迫使製造商和經銷商重新評估其人工呼吸器、監護設備、注射器以及某些活性藥物成分關鍵組件的籌資策略。在許多情況下，供應商在短期內承擔了邊際成本，但關稅的長期影響迫使他們與醫療系統重新談判價格，並重新協商商業合約。

從產品、給藥途徑、患者人口統計、治療用途和醫療保健環境的角度，確定臨床、採購和創新重點，並以細分觀點主導。

精準的細分觀點闡明了臨床需求、採購優先順序和創新如何在產品類型、給藥途徑、患者族群、治療應用和終端使用者環境等因素之間相互交織。基於產品類型，重點在於植入式醫療設備、靜脈輸液袋、藥品、監測設備、注射器和導管以及人工呼吸器。藥品進一步細分為抗生素、神經肌肉阻斷劑、鎮靜劑和血栓溶解劑，以反映不同的臨床方案和供應途徑。基於給藥途徑，吸入、靜脈注射和口服給藥各有不同的性能特徵和普及率，每種給藥途徑在監管、儲存和給藥方面也面臨不同的挑戰，從而影響採購和床邊工作流程。

決定美洲、歐洲、中東和非洲以及亞太地區臨床引入、監管准入和供應鏈韌性的區域策略趨勢。

區域趨勢持續影響著美洲、歐洲、中東和非洲（EMEA）以及亞太地區的臨床應用、監管時間表和供應商企業發展，每個地區都為製造商和醫療服務提供者帶來了獨特的優勢和挑戰。在美洲，完善的報銷機制和一體化的醫院系統為循證技術創造了有利環境，這些技術能夠顯著縮短住院時間和減少併發症；然而，這些市場面臨著嚴格的檢驗審查和競爭性競標，尤其注重已驗證的臨床結果。

市場領導之間的競爭行為和策略挑戰，結合產品整合、證據產生和供應鏈強化。

主要企業之間的競爭動態反映了雙重需求：既要維持營運韌性，又要加速臨床差異化。為了獲得永續的競爭優勢，企業正致力於投資整合醫療設備和分析能力、完善的上市後監測以及能夠保障持續收入的耗材生態系統的整合解決方案。許多領導企業正在推行模組化平台策略，實現分階段升級而無需徹底更換，從而減輕醫院資本投資負責人的負擔，並促進臨床環境中的平穩過渡。

產業領導者可以採取哪些優先可行的步驟來增強供應鏈韌性、臨床部署和實證差異化？

產業領導企業應優先採取一系列高影響力行動，將洞察轉化為可衡量的改進，從而提升產品的可用性、臨床性能和商業性競爭力。首先，透過投資互通性標準和以臨床醫生為中心的設計，使產品路線藍圖與臨床工作流程保持一致。這可以降低採用門檻，並提高新型監測和呼吸器技術成為標準實踐的可能性。其次，實現製造地和供應商基礎的多元化，以降低關稅風險和物流中斷的影響。在採購合約中加入近岸外包和多源採購條款，以確保在面對地緣政治或貿易變化時業務永續營運。

一種透明的、基於三角測量的調查方法，結合了初步臨床訪談、系統性的二次檢驗和情境測試，以支援策略決策。

本分析所採用的研究途徑結合了結構化的初步研究和系統的二次檢驗，以確保結論是基於證據且具有實際意義。初步研究包括對急診護理機構的臨床負責人、採購負責人和供應鏈主管進行訪談，從而獲得關於設備可用性、治療方法選擇和庫存管理實踐的第一手觀點。這些定性研究結果與產品生命週期文件、監管申報文件和公開的臨床試驗報告進行交叉比對，以檢驗設備推廣應用的促進因素和風險因素。

策略結論強調互通性、採購韌性和實證方案是改善結果和實現永續競爭優勢的途徑。

總之，在臨床創新、健全的採購體系和日益成長的地緣政治敏感性的驅動下，重症監護醫療設備正在經歷一場結構性變革。對更佳治療效果的需求、更嚴格的採購審查以及政策驅動的貿易中斷等多重壓力，迫使各企業在產品設計、供應鏈建構和實證實踐方面做出調整。那些能夠將與臨床工作流程的兼容性、健全的採購體係以及有針對性的真實世界檢驗相結合的企業，將為產品推廣鋪平道路，並確立強大的市場地位。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：重症監護藥物市場：依產品類型分類

  • 植入式醫療設備
  • 靜脈輸液袋
  • 製藥
    • 抗生素
    • 神經肌肉阻斷劑
    • 鎮靜劑
    • 溶栓劑
  • 監控設備
  • 注射器和導管
  • 人工呼吸器

第9章：重症監護藥物市場依給藥途徑分類

  • 吸入
  • 靜脈
  • 口服

第10章：依病患細分分類的重症監護藥物市場

  • 成年患者
  • 老年患者
  • 新生兒加護病房（NICU）
  • 兒童患者

第11章：按治療應用分類的重症監護藥物市場

  • 循環系統護理
  • 緊急復甦
  • 神經系統疾病
    • 顱內壓監測
    • 創傷性腦損傷
  • 腎臟替代療法
  • 呼吸護理
    • 氣喘
    • 慢性阻塞性肺病
    • 肺水腫

第12章 重症監護藥物市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 長期照護機構

第13章：重症監護藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 重症監護藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 重症監護藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國重症監護藥物市場

第17章：中國重症監護藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Aspen Group
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio Products Laboratory Ltd.
  • Collegium Pharmaceutical, Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Grifols SA
  • Johnson & Johnson
  • Kedrion Spa
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Shanghai RAAS
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 1.48 billion in 2025 and is projected to grow to USD 1.57 billion in 2026, with a CAGR of 5.66%, reaching USD 2.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.48 billion
Estimated Year [2026] USD 1.57 billion
Forecast Year [2032] USD 2.18 billion
CAGR (%) 5.66%

An integrative overview that frames clinical priorities, operational pressures, and strategic implications shaping the future of critical care therapeutics

The critical care therapeutics landscape sits at a strategic crossroads where clinical imperative, technological advancement, and policy dynamics converge. Health systems and procurement leaders face pressure to integrate more resilient supply chains, adopt evidence-driven therapeutics and devices, and align capital allocation with emerging clinical priorities. This introduction frames the analysis that follows by situating the reader within the broader forces shaping clinical practice, device utilization, and therapeutic selection across acute care settings.

This report synthesizes regulatory developments, clinical innovation, and operational stressors that together reshape how critical care is delivered. Readers should expect concise, actionable insight that bridges clinical need with commercial strategy, helping manufacturers, providers, and payers prepare for accelerating demand for integrated monitoring solutions, advanced ventilatory support, and targeted medication protocols. By grounding the discussion in real-world drivers rather than speculative projections, the introduction sets the tone for a pragmatic review focused on adoption barriers, supply dynamics, and strategic opportunities.

How innovations in monitoring, therapeutics, and value-based incentives are remapping clinical pathways and supply chain priorities in critical care

Over the past several years, transformative shifts have reconfigured the critical care landscape, driven by converging advances in monitoring, pharmacology, and systems resilience. Remote-capable monitoring devices and closed-loop infusion systems have migrated from prototype to clinical deployment, changing the cadence of bedside management and enabling earlier detection of physiologic decline. At the same time, pharmacologic optimization-particularly in sedation strategies and neuromuscular blockade-has sharpened focus on protocols that reduce ventilation time and downstream complications.

Payment reforms and value-based purchasing models have further incentivized reductions in length of stay and readmission rates, prompting hospitals to adopt technologies and therapeutics that demonstrably improve throughput and patient outcomes. Parallel to these clinical and economic drivers, capital flows have increasingly favored integrated solutions that combine device telemetry, analytics, and consumable therapies, accelerating partnership models between device makers and software providers. The combined effect is an ecosystem that rewards interoperability, evidence of clinical benefit, and supply chain transparency, shifting competitive advantage toward organizations that can deliver end-to-end clinical value.

Assessing the operational and procurement consequences of the 2025 US tariff measures and how they reshaped sourcing, pricing resilience, and clinical continuity

The cumulative impact of the United States tariffs implemented in 2025 introduced material frictions across procurement, manufacturing, and clinical operations, prompting immediate strategic responses across the value chain. Tariff-driven input cost inflation has required manufacturers and distributors to reassess sourcing strategies for key components used in ventilators, monitoring devices, syringes, and certain active pharmaceutical ingredients. In many instances, suppliers absorbed marginal costs short term, but persistent tariff exposure has forced price renegotiation and commercial re-contracting with health systems.

Clinicians and hospital supply teams responded by prioritizing suppliers with diversified production bases and clearer contingency planning, while purchasing departments accelerated qualification of alternate vendors to avoid single-source vulnerability. Where tariffs intersected with regulatory requirements for specific device specifications or medication formulations, lead times extended as manufacturers worked to relocate production or certify new facilities. The net operational consequence was an increased emphasis on inventory buffer strategies, tighter coordination between clinical and procurement teams, and contractual clauses that transfer or mitigate tariff risk. Looking forward, organizations that institutionalize dynamic sourcing, nearshoring, and transparent landed-cost modeling will navigate tariff disruptions more effectively and protect continuity of critical care delivery.

Segment-driven perspectives that pinpoint clinical, procurement, and innovation priorities across products, routes, demographics, therapeutic use cases, and care settings

A nuanced segmentation lens clarifies where clinical demand, procurement priority, and innovation converge across product types, administration routes, patient demographics, therapeutic applications, and end-user environments. Based on product type, attention concentrates on implantable devices, intravenous infusion bags, medications, monitoring devices, syringes & catheters, and ventilators, with medications further differentiated by antibiotics, neuromuscular blockers, sedatives, and thrombolytics to reflect distinct clinical protocols and supply pathways. Based on administration routes, performance and adoption vary across inhalation, intravenous, and oral delivery, each carrying different regulatory, storage, and administration implications that influence procurement and bedside workflows.

Patient demographics create differentiated demand profiles: adult patients, geriatric patients, neonatal intensive care patients, and pediatric patients each present unique physiological considerations, dosing challenges, and device sizing requirements that shape product development and procurement specifications. Therapeutic application segmentation highlights where specialty capabilities concentrate, spanning cardiovascular care, emergency resuscitation, neurological disorders, renal replacement therapy, and respiratory care; neurological disorders are parsed into intracranial pressure monitoring and traumatic brain injury, while respiratory care subdivides into asthma, chronic obstructive pulmonary disease, and pulmonary edema to reflect distinct clinical pathways. Finally, the end-user segmentation-ambulatory surgical centers, home healthcare, hospitals, and long-term care facilities-defines differences in purchasing cycles, capital budgets, and staff competencies, all of which influence adoption velocity and lifecycle support expectations.

Integrating these segmentation axes reveals high-priority intersections: for example, monitoring devices paired with geriatric patients in hospital settings demand interoperability and geriatric-specific algorithms, whereas intravenous infusion bags and neuromuscular blockers used in emergency resuscitation require streamlined logistics and rapid availability. The segmentation-driven view underscores the need for tailored go-to-market strategies that align product design, regulatory planning, and commercialization with the operational realities of each clinical niche.

Regional strategic dynamics that determine clinical adoption, regulatory access, and supply chain resilience across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape clinical adoption, regulatory timelines, and supplier footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct advantages and constraints for manufacturers and providers. In the Americas, established reimbursement pathways and consolidated hospital systems create a fertile environment for evidence-based technologies that demonstrably reduce length of stay and complications, but the same markets also impose rigorous procurement scrutiny and competitive tendering that favor validated clinical outcomes.

Europe, Middle East & Africa presents a heterogeneous regulatory and payer landscape where national-level reimbursement policies and varied purchasing consortiums influence entry strategy; in many jurisdictions, regional procurement frameworks and public tendering demand extensive documentation of comparative effectiveness and lifecycle costs. In the Asia-Pacific region, rapid capacity expansion, growing investment in critical care infrastructure, and supplier ecosystems that span mature and emerging manufacturing hubs create opportunities for cost-competitive innovation, though regulatory harmonization remains a work in progress. Across these geographies, lead-time considerations, localization of service networks, and regulatory alignment are the primary determinants of commercial success, and organizations that invest in regional clinical evidence generation and localized supply chain resilience will see superior adoption outcomes.

Competitive behaviors and strategic imperatives among market leaders that combine product integration, evidence generation, and supply chain fortification

Competitive dynamics among leading firms reflect a dual imperative: sustain operational resilience while accelerating clinical differentiation. Companies that secure durable advantage have focused investments on integrated solutions that pair devices with analytics, robust post-market surveillance, and consumable ecosystems that lock in recurring revenue. Many leaders pursue modular platform strategies that allow incremental upgrades without wholesale replacement, reducing friction for hospital capital planners and enabling smoother clinical transitions.

Strategic partnerships have proliferated between device manufacturers, software integrators, and specialty pharmaceutical suppliers to enable bundled value propositions that address both clinical outcomes and cost-of-care metrics. Meanwhile, vertical integration-especially around sterilization, component supply, and regional manufacturing-reduces exposure to cross-border tariff and transportation shocks. Talent acquisition around regulatory affairs, health economics, and clinical evidence generation has become central to sustaining market access, as payers and procurement teams increasingly demand rigorous real-world performance data. Companies that balance rapid product iteration with disciplined post-market validation and regional service networks are better positioned to retain customer relationships and expand into adjacent therapeutic applications.

Prioritized practical actions that industry leaders can implement to strengthen supply chain resilience, clinical adoption, and evidence-driven differentiation

Industry leaders should prioritize a set of high-impact actions that translate insight into measurable improvements in availability, clinical performance, and commercial traction. First, align product roadmaps with clinical workflows by investing in interoperability standards and clinician-centered design; this reduces adoption friction and increases the probability that new monitoring and ventilation technologies become standard of care. Second, diversify manufacturing and supplier bases to mitigate tariff exposure and logistics disruptions, incorporating nearshoring and multi-sourcing clauses into procurement contracts to preserve continuity during geopolitical or trade shifts.

Third, accelerate robust real-world evidence generation through coordinated post-market studies and registry participation, coupling clinical endpoints with economic outcomes to support procurement negotiations and payer discussions. Fourth, develop tiered commercial models that reflect the differentiated needs of hospitals, ambulatory surgical centers, home healthcare, and long-term care facilities, enabling teams to tailor pricing, support, and training to end-user capabilities. Finally, invest in workforce capability building-clinical education, maintenance training, and digital literacy-to ensure technology deployments translate into better patient outcomes and strengthened customer loyalty. Executing these actions in sequence and in parallel will create resilient adoption pathways and durable competitive edges.

A transparent, triangulated research methodology combining primary clinical interviews, systematic secondary validation, and scenario testing to support strategic decisions

The research approach employed for this analysis combines structured primary inquiry with systematic secondary validation to ensure conclusions are evidence-based and operationally relevant. Primary research included targeted interviews with clinical leaders, procurement officers, and supply chain executives across acute care settings, enabling the capture of frontline perspectives on device usability, therapeutic selection, and inventory management practices. These qualitative insights were triangulated with product lifecycle documentation, regulatory filings, and publicly available clinical study reports to validate adoption drivers and risk vectors.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and non-proprietary industry publications to contextualize clinical trends and technological trajectories. A rigorous triangulation framework reconciled disparate data points, while methodological safeguards-such as cross-respondent validation, temporal sensitivity checks, and provenance tracking-ensured robust inference. Where relevant, scenario testing assessed operational implications of supply disruptions and policy shifts, and sensitivity analysis informed recommendations related to sourcing and evidence generation. The methodology prioritizes transparency, reproducibility, and relevance to strategic decision-making within clinical and commercial teams.

A strategic conclusion emphasizing interoperability, sourcing resilience, and evidence programs as the pathway to improved outcomes and durable competitive advantage

In conclusion, critical care therapeutics are undergoing structural evolution driven by clinical innovation, procurement discipline, and heightened geopolitical sensitivity. The combined pressures of demands for better outcomes, tighter procurement scrutiny, and policy-driven trade disruptions require organizations to adapt across product design, supply chain architecture, and evidence generation. Those that integrate clinical workflow compatibility with resilient sourcing and focused real-world validation will unlock adoption pathways and create defensible market positions.

The strategic imperative for stakeholders is clear: prioritize interoperability and clinician usability, diversify supplier footprints to mitigate tariff and logistics risk, and construct evidence programs that link clinical outcomes to economic value. By doing so, manufacturers and providers can improve patient outcomes while insulating operations against the volatility of global trade and regulatory change. The insights and recommendations presented here provide a practical blueprint for translating current industry dynamics into durable competitive advantage and improved care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Critical Care Therapeutics Market, by Product Type

  • 8.1. Implantable Devices
  • 8.2. Intravenous Infusion Bags
  • 8.3. Medications
    • 8.3.1. Antibiotics
    • 8.3.2. Neuromuscular Blockers
    • 8.3.3. Sedatives
    • 8.3.4. Thrombolytics
  • 8.4. Monitoring Devices
  • 8.5. Syringes & Catheters
  • 8.6. Ventilators

9. Critical Care Therapeutics Market, by Administration Routes

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Critical Care Therapeutics Market, by Patient Demographics

  • 10.1. Adult Patients
  • 10.2. Geriatric Patients
  • 10.3. Neonatal Intensive Care Patients (NICU)
  • 10.4. Pediatric Patients

11. Critical Care Therapeutics Market, by Therapeutic Application

  • 11.1. Cardiovascular Care
  • 11.2. Emergency Resuscitation
  • 11.3. Neurological Disorders
    • 11.3.1. Intracranial Pressure Monitoring
    • 11.3.2. Traumatic Brain Injury
  • 11.4. Renal Replacement Therapy
  • 11.5. Respiratory Care
    • 11.5.1. Asthma
    • 11.5.2. Chronic Obstructive Pulmonary Disease
    • 11.5.3. Pulmonary Edema

12. Critical Care Therapeutics Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Long-Term Care Facilities

13. Critical Care Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Critical Care Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Critical Care Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Critical Care Therapeutics Market

17. China Critical Care Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abeona Therapeutics Inc.
  • 18.7. ADMA Biologics, Inc.
  • 18.8. Albumedix Ltd. by Sartorius AG
  • 18.9. Aspen Group
  • 18.10. Bayer AG
  • 18.11. Becton, Dickinson and Company
  • 18.12. Bio Products Laboratory Ltd.
  • 18.13. Collegium Pharmaceutical, Inc.
  • 18.14. CSL Limited
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline plc
  • 18.18. Grifols SA
  • 18.19. Johnson & Johnson
  • 18.20. Kedrion Spa
  • 18.21. Merck & Co., Inc.
  • 18.22. Novartis AG
  • 18.23. Octapharma AG
  • 18.24. Pfizer Inc.
  • 18.25. Roche Holding AG
  • 18.26. Sanofi S.A.
  • 18.27. Shanghai RAAS
  • 18.28. Siemens Healthineers AG
  • 18.29. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEONATAL INTENSIVE CARE PATIENTS (NICU), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)